Free Access
Issue |
Med Sci (Paris)
Volume 33, Number 11, Novembre 2017
|
|
---|---|---|
Page(s) | 1003 - 1006 | |
Section | Forum | |
DOI | https://doi.org/10.1051/medsci/20173311020 | |
Published online | 04 December 2017 |
- Communiqué de la FDA : https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. [Google Scholar]
- Champiat S, Soria JC. Nouvelles pratiques en immuno-oncologie : une révolution et un immense défi scientifique et médical. Med Sci (Paris) 2017 ; 33 : 563–564. [Google Scholar]
- Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010 ; 116 : 4099–4102. [Google Scholar]
- Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017 08 31. 10.1038/nrclinonc.2017.128 [Google Scholar]
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014 ; 371 : 1507–1517. [Google Scholar]
- Communiqué de Novartis : https://novartis.gcs-web.com/novartis-receives-fda-approval-for-KymriahTM. [Google Scholar]
- Étude sur les CAR-T par NICE (2015): https://www.nice.org.uk/Media/Default/About/what-we-do/Science%20policy%20and%20research/final-york-report-march-16.pdf. [Google Scholar]
- Estimation du coût de fabrication de Kymriah : https://www.reuters.com/article/us-novartis-fda-price/profit-on-475000-novartis-cancer-drug-could-be-a-while-coming-idUSKCN1BB2EA. [Google Scholar]
- Jordan B. Les débuts de CRISPR en thérapie génique. Med Sci (Paris) 2016 ; 32 : 1035–1037. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex genome-edited T-cell manufacturing platform for “Off-the-Shelf” adoptive T-cell immunotherapies. Cancer Res 2015 ; 75 : 3853–3864. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.